Kidney failure after treatment with 90Y-DOTATOC [1]

European Journal of Nuclear Medicine

Volumn 29, Issue 3, 2002, Pages 435-

  Schumacher, Tilmann ^a   Waldherr, Christian ^a   Mueller Brand, Jan ^a   Maecke, Helmut ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; DOTATOC; PEPTIDE; RADIOACTIVE IODINE; UNCLASSIFIED DRUG; YTTRIUM 90;

ANAMNESIS; CANCER CHEMOTHERAPY; CASE REPORT; DECISION MAKING; DRUG ABSORPTION; FEMALE; FOLLOW UP; HUMAN; HYDRONEPHROSIS; IRRADIATION; ISOTOPE LABELING; KIDNEY BLOOD VESSEL; KIDNEY FAILURE; KIDNEY TUBULE ABSORPTION; KIDNEY TUMOR; LETTER; MICROANGIOPATHY; NEPHROTOXICITY; PATIENT EDUCATION; RADIATION INJURY; RECEPTOR DENSITY; THROMBOSIS; TUMOR VOLUME; URINARY TRACT INFECTION;

AGED; CARCINOID TUMOR; FEMALE; HUMANS; INTESTINAL NEOPLASMS; KIDNEY FAILURE, CHRONIC; OCTREOTIDE; RADIATION INJURIES; YTTRIUM RADIOISOTOPES;

EID: 0036206998     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-001-0720-2     Document Type: Letter

References (8)

1. 90Y-DOTATOC
2. Between the Scylla and Charybdis of peptide radionuclide therapy: Hitting the tumor and saving the kidney
3. Yttrium-90 Dotatoc: First clinical results
4. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue
5. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives
6. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations
7. D-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake
8. A new cause of renal thrombotic microangiopathy: Yttrium 90-DOTATOC internal radiotherapy